Castle Biosciences Inc. (CSTL) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Castle Biosciences Inc. (CSTL) surged +4.99% to $38.51, trading at 78% of its 52-week range ($17.72 – $44.28). Solid 79% profit margin (-9% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephe
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CSTL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CSTL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Castle Biosciences Inc. (CSTL) ranks #203 by composite RQD confidence (60/100, grade C-) and #339 by equity capitalization ($1.18B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with CSTL at 60/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CSTL
ACTIVE
Castle Biosciences Inc. | C- | 60/100 | — | 79.4% | -9.3% | +4.99% | $1.18B | Benchmark Subject |
| LMRI Lumexa Imaging Holdings Inc. | D+ | 58/100 | — | — | — | +0.95% | $1.13B | /lmri-vs-cstl → |
| TRUP Trupanion Inc. | C | 64/100 | 68.2x | 16.1% | 3.1% | +2.27% | $1.32B | /trup-vs-cstl → |
| FRNM Freenome Inc. | E | 31/100 | — | — | -3.4% | -4.32% | $1.38B | /frnm-vs-cstl → |
| ALHC Alignment Healthcare Inc. | C+ | 67/100 | — | — | 13.9% | -1.47% | $1.67B | /alhc-vs-cstl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Castle Biosciences Inc. (CSTL) reported GAAP revenue of $344.2M (+3.7% vs. FY2024 revenue of $332.1M , and +56.6% cumulative change since FY2023) , GAAP net income of -$24.2M, operating cash flow of $64.3M, and free cash flow of $28.3M (-22.5% YoY). On the balance sheet, CSTL closed FY2025 with $578.6M in total assets against $9.6M in total debt (Altman Z-Score: 6.97, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $344.2M | -$24.2M | $64.3M | $28.3M | $578.6M | $9.6M |
| FY2024 (FY) | 2024-12-31 | $332.1M | $18.2M | $64.9M | $36.5M | $531.2M | $9.7M |
| FY2023 (FY) | 2023-12-31 | $219.8M | -$57.5M | -$5.6M | -$5.6M | — | — |
As of 2026-11-01, Castle Biosciences Inc. (NASDAQ: CSTL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $38.51 (+4.99% 1D, market cap $1.18B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CSTL ranks #203 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), CSTL carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of -9.3%. By comparison, LMRI (Lumexa Imaging Holdings Inc.) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.13B) and TRUP (Trupanion Inc.) posts a C grade (64/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
Per CSTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447362), Castle Biosciences Inc. generated $344.2M in revenue (+3.7% YoY), -$24.2M in net income, and $28.3M in free cash flow against $578.6M in total assets and $9.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CSTL last traded at $38.51 (+4.99% on volume of 723,935 shares), positioning the stock +12.54% above its 50-day simple moving average ($34.22) and +34.98% above its 200-day simple moving average ($28.53). Across its 52-week range of $17.72 to $44.28, CSTL sits at the 78.3% percentile with a 14-day RSI of 60.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.2% ($34.20 to $42.82).
Why CSTL Stock surged +4.99% Today — RQD Quant Desk Flash. Solid 79% profit margin (-9% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.